|1.||Hadden, John W: 9 articles (06/2012 - 08/2003)|
|2.||Naylor, Paul H: 6 articles (06/2012 - 09/2007)|
|3.||Whiteside, Theresa L: 5 articles (01/2013 - 04/2011)|
|4.||Egan, James E: 4 articles (06/2012 - 01/2011)|
|5.||Hadden, J W: 4 articles (05/2009 - 03/2000)|
|6.||Verastegui, E: 4 articles (09/2007 - 03/2000)|
|7.||Brandwein, Harvey J: 3 articles (06/2012 - 10/2010)|
|8.||Baltzer, Lorraine: 3 articles (06/2012 - 04/2011)|
|9.||Wolf, Gregory T: 3 articles (06/2012 - 01/2009)|
|10.||Berinstein, Neil L: 3 articles (06/2012 - 01/2011)|
09/01/2007 - "Although IRX-2 was effective alone (using doses that contain significantly less IL-2 than in most typical studies), adding Talpha1 led to significant improvement in survival of the tumor-bearing mice. "
10/08/2010 - "Based on these studies, IRX-2 is a candidate for evaluation as a T cell adjuvant in a variety of preclinical vaccine delivery systems as well as in human clinical trials with cancer vaccine candidates."
09/01/2007 - "Clinical studies with IRX-2 showed increases of T lymphocytes in lymphocytopenic cancer patients but relatively little effect on irradiated, lymphocytopenic patients. "
06/01/2002 - "The objective of this study was to evaluate the antitumor activity and toxicity of IRX-2 in untreated early stage cervical cancer patients. "
01/01/2013 - "In a recent phase II clinical trial for HNSCC patients, IRX-2, a cell-derived biologic, promoted T-cell infiltration into the tumor and prolonged overall survival. "
|4.||Squamous Cell Neoplasms (Squamous Cell Cancer)
09/01/2012 - "IRX-2 is a primary biologic which has been used for the therapy of head and neck squamous cell cancer (HNSCC) with promising clinical results. "
06/01/2012 - "Twenty-seven subjects with squamous cell cancer of the head and neck received the neoadjuvant IRX-2 immunotherapy regimen prior to surgery in a Phase 2 trial. "
06/01/2012 - "IRX-2, a primary cell-derived biologic with pleotropic immune activity, was shown to induce increased lymphocyte infiltrations into the tumor of patients with head and neck squamous cell cancer (HNSCC) after 10 days of neoadjuvant therapy (Berinstein et al. 2011). "
08/01/2003 - "A Phase II trial in 42 patients with squamous cell cancer of the head and neck (H and NSCC) was performed using a combination immunotherapy with 10-20 days of perilymphatic injections of a natural cytokine mixture (NCM: IRX-2; 200 units IL-2 equivalence) preceded by low dose cyclophosphamide (CY; 300 mg/m(2)) and followed by daily oral indomethacin (25 mg t.i.d.) and zinc (65 mg in a multivitamin preparation). "
|5.||Head and Neck Neoplasms (Head and Neck Cancer)
06/01/2012 - "Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen."
08/01/2003 - "Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2."
08/01/2003 - "In studies of combination immunotherapy in lymphocytopenic squamous cell head and neck cancer patients using IRX-2 (18 patients) and IRX-2 plus thymosin alpha(1) (IRX-3) in IRX-2-refractory patients (7 patients), marked increases in CD(45)RA(+) 'naïve' T cells (>250/mm(3)) were observed. "
|8.||Interleukin-12 (IL 12)
|9.||Interferon-alpha (Interferon Alfa)
|4.||Drug Therapy (Chemotherapy)